Literature DB >> 30205049

Mutant NPM1 Maintains the Leukemic State through HOX Expression.

Lorenzo Brunetti1, Michael C Gundry2, Daniele Sorcini3, Anna G Guzman4, Yung-Hsin Huang5, Raghav Ramabadran6, Ilaria Gionfriddo3, Federica Mezzasoma3, Francesca Milano3, Behnam Nabet7, Dennis L Buckley8, Steven M Kornblau9, Charles Y Lin10, Paolo Sportoletti3, Maria Paola Martelli3, Brunangelo Falini3, Margaret A Goodell11.   

Abstract

NPM1 is the most frequently mutated gene in cytogenetically normal acute myeloid leukemia (AML). In AML cells, NPM1 mutations result in abnormal cytoplasmic localization of the mutant protein (NPM1c); however, it is unknown whether NPM1c is required to maintain the leukemic state. Here, we show that loss of NPM1c from the cytoplasm, either through nuclear relocalization or targeted degradation, results in immediate downregulation of homeobox (HOX) genes followed by differentiation. Finally, we show that XPO1 inhibition relocalizes NPM1c to the nucleus, promotes differentiation of AML cells, and prolongs survival of Npm1-mutated leukemic mice. We describe an exquisite dependency of NPM1-mutant AML cells on NPM1c, providing the rationale for the use of nuclear export inhibitors in AML with mutated NPM1.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AML; CRISPR; HOX; MEIS1; NPM1; XPO1; acute myeloid leukemia; dTAG; nuclear export; selinexor

Mesh:

Substances:

Year:  2018        PMID: 30205049      PMCID: PMC6159911          DOI: 10.1016/j.ccell.2018.08.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  70 in total

1.  Role of nucleophosmin in embryonic development and tumorigenesis.

Authors:  Silvia Grisendi; Rosa Bernardi; Marco Rossi; Ke Cheng; Luipa Khandker; Katia Manova; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

2.  Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation.

Authors:  G Sauvageau; U Thorsteinsdottir; M R Hough; P Hugo; H J Lawrence; C Largman; R K Humphries
Journal:  Immunity       Date:  1997-01       Impact factor: 31.745

3.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Authors:  Ramesh Balusu; Warren Fiskus; Rekha Rao; Daniel G Chong; Srilatha Nalluri; Uma Mudunuru; Hongwei Ma; Lei Chen; Sreedhar Venkannagari; Kyungsoo Ha; Sunil Abhyankar; Casey Williams; Joseph McGuirk; Hanna Jean Khoury; Celalettin Ustun; Kapil N Bhalla
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Embryonic stem cell-derived hematopoietic stem cells.

Authors:  Yuan Wang; Frank Yates; Olaia Naveiras; Patricia Ernst; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-15       Impact factor: 11.205

6.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

7.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.

Authors:  H Quentmeier; M P Martelli; W G Dirks; N Bolli; A Liso; R A F Macleod; I Nicoletti; R Mannucci; A Pucciarini; B Bigerna; M F Martelli; C Mecucci; H G Drexler; B Falini
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

8.  deepTools: a flexible platform for exploring deep-sequencing data.

Authors:  Fidel Ramírez; Friederike Dündar; Sarah Diehl; Björn A Grüning; Thomas Manke
Journal:  Nucleic Acids Res       Date:  2014-05-05       Impact factor: 16.971

9.  A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.

Authors:  A Mupo; L Celani; O Dovey; J L Cooper; C Grove; R Rad; P Sportoletti; B Falini; A Bradley; G S Vassiliou
Journal:  Leukemia       Date:  2013-03-12       Impact factor: 11.528

10.  ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors.

Authors:  Christian Schmidl; André F Rendeiro; Nathan C Sheffield; Christoph Bock
Journal:  Nat Methods       Date:  2015-08-17       Impact factor: 28.547

View more
  73 in total

1.  Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.

Authors:  Hannah J Uckelmann; Stephanie M Kim; Eric M Wong; Charles Hatton; Hugh Giovinazzo; Jayant Y Gadrey; Andrei V Krivtsov; Frank G Rücker; Konstanze Döhner; Gerard M McGeehan; Ross L Levine; Lars Bullinger; George S Vassiliou; Scott A Armstrong
Journal:  Science       Date:  2020-01-31       Impact factor: 47.728

2.  Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer.

Authors:  Fei Li; Wai-Lung Ng; Troy A Luster; Hai Hu; Vladislav O Sviderskiy; Catríona M Dowling; Kate E R Hollinshead; Paula Zouitine; Hua Zhang; Qingyuan Huang; Michela Ranieri; Wei Wang; Zhaoyuan Fang; Ting Chen; Jiehui Deng; Kai Zhao; Hon-Cheong So; Alireza Khodadadi-Jamayran; Mousheng Xu; Angeliki Karatza; Val Pyon; Shuai Li; Yuanwang Pan; Kristen Labbe; Christina Almonte; John T Poirier; George Miller; Richard Possemato; Jun Qi; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2020-07-09       Impact factor: 12.701

Review 3.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

4.  Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.

Authors:  Justin Taylor; Maria Sendino; Alexander N Gorelick; Alessandro Pastore; Matthew T Chang; Alexander V Penson; Elena I Gavrila; Connor Stewart; Ella M Melnik; Florisela Herrejon Chavez; Lillian Bitner; Akihide Yoshimi; Stanley Chun-Wei Lee; Daichi Inoue; Bo Liu; Xiao J Zhang; Anthony R Mato; Ahmet Dogan; Michael G Kharas; Yuhong Chen; Demin Wang; Rajesh K Soni; Ronald C Hendrickson; Gorka Prieto; Jose A Rodriguez; Barry S Taylor; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-07-08       Impact factor: 39.397

5.  Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Authors:  Kendra Sweet; Rami Komrokji; Eric Padron; Christopher L Cubitt; Joel G Turner; Junmin Zhou; Alan F List; David A Sallman; Jana L Dawson; Daniel M Sullivan; Julio Chavez; Bijal D Shah; Jeffrey E Lancet
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

6.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

Authors:  Peter van Galen; Volker Hovestadt; Marc H Wadsworth Ii; Travis K Hughes; Gabriel K Griffin; Sofia Battaglia; Julia A Verga; Jason Stephansky; Timothy J Pastika; Jennifer Lombardi Story; Geraldine S Pinkus; Olga Pozdnyakova; Ilene Galinsky; Richard M Stone; Timothy A Graubert; Alex K Shalek; Jon C Aster; Andrew A Lane; Bradley E Bernstein
Journal:  Cell       Date:  2019-02-28       Impact factor: 41.582

7.  NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Authors:  Guillermo Montalban-Bravo; Rashmi Kanagal-Shamanna; Koji Sasaki; Keyur Patel; Irene Ganan-Gomez; Elias Jabbour; Tapan Kadia; Farhad Ravandi; Courtney DiNardo; Gautham Borthakur; Koichi Takahashi; Marina Konopleva; Rami S Komrokji; Amy DeZern; Teodora Kuzmanovic; Jaroslaw Maciejewski; Sherry Pierce; Simona Colla; Mikkael A Sekeres; Hagop Kantarjian; Carlos Bueso-Ramos; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2019-03-26

Review 8.  CTCF-mediated genome organization and leukemogenesis.

Authors:  Yi Qiu; Suming Huang
Journal:  Leukemia       Date:  2020-06-09       Impact factor: 11.528

Review 9.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

Review 10.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.